Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.
Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.